116 related articles for article (PubMed ID: 38644612)
1. Extramedullary infiltration in pediatric acute myeloid leukemia: Results from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative.
Li W; Shi M; Zhou P; Liu Y; Liu X; Xiao X; Zuo S; Bai Y; Sun K
Pediatr Blood Cancer; 2024 Jul; 71(7):e31014. PubMed ID: 38644612
[TBL] [Abstract][Full Text] [Related]
2. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
Pollard JA; Guest E; Alonzo TA; Gerbing RB; Loken MR; Brodersen LE; Kolb EA; Aplenc R; Meshinchi S; Raimondi SC; Hirsch B; Gamis AS
J Clin Oncol; 2021 Oct; 39(28):3149-3160. PubMed ID: 34048275
[TBL] [Abstract][Full Text] [Related]
3. Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia.
Kobayashi R; Tawa A; Hanada R; Horibe K; Tsuchida M; Tsukimoto I;
Pediatr Blood Cancer; 2007 Apr; 48(4):393-8. PubMed ID: 16550530
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Impact of Extramedullary Infiltration in Pediatric Low-risk Acute Myeloid Leukemia: A Retrospective Single-center Study Over 10 Years.
Hu GH; Lu AD; Jia YP; Zuo YX; Wu J; Zhang LP
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e813-e820. PubMed ID: 32680776
[TBL] [Abstract][Full Text] [Related]
5. Extramedullary Infiltration in Pediatric Acute Myeloid Leukemia on Surveillance Magnetic Resonance Imaging and its Relationship With Established Risk Factors.
Kim EH; Im SA; Lee JW; Kim S; Cho B
J Pediatr Hematol Oncol; 2022 Apr; 44(3):e713-e718. PubMed ID: 35319510
[TBL] [Abstract][Full Text] [Related]
6. Myeloid sarcoma is associated with poor clinical outcome in pediatric patients with acute myeloid leukemia.
Xu LH; Wang Y; Chen ZY; Fang JP
J Cancer Res Clin Oncol; 2020 Apr; 146(4):1011-1020. PubMed ID: 31919567
[TBL] [Abstract][Full Text] [Related]
7. Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
Tarlock K; Alonzo TA; Gerbing RB; Raimondi SC; Hirsch BA; Sung L; Pollard JA; Aplenc R; Loken MR; Gamis AS; Meshinchi S
Clin Cancer Res; 2016 Apr; 22(8):1951-7. PubMed ID: 26644412
[TBL] [Abstract][Full Text] [Related]
8. Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis.
Xu Q; He S; Yu L
Front Immunol; 2021; 12():683595. PubMed ID: 34484181
[TBL] [Abstract][Full Text] [Related]
9. Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01.
De Moerloose B; Reedijk A; de Bock GH; Lammens T; de Haas V; Denys B; Dedeken L; van den Heuvel-Eibrink MM; Te Loo M; Uyttebroeck A; Van Damme A; Van der Werff-Ten Bosch J; Zsiros J; Kaspers G; de Bont E
Pediatr Blood Cancer; 2019 May; 66(5):e27605. PubMed ID: 30623572
[TBL] [Abstract][Full Text] [Related]
10. Children with acute myeloblastic leukemia presenting with extramedullary infiltration: the effects of high-dose steroid treatment.
Hiçsönmez G; Cetin M; Tuncer AM; Yenicesu I; Aslan D; Ozyürek E; Unal S
Leuk Res; 2004 Jan; 28(1):25-34. PubMed ID: 14630077
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G;
Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637
[TBL] [Abstract][Full Text] [Related]
12. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
13. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
Döhner H; Weber D; Krzykalla J; Fiedler W; Kühn MWM; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Fransecky L; Koller E; Wulf G; Schleicher J; Ringhoffer M; Greil R; Hertenstein B; Krauter J; Martens UM; Nachbaur D; Samra MA; Machherndl-Spandl S; Basara N; Leis C; Schrade A; Kapp-Schwoerer S; Cocciardi S; Bullinger L; Thol F; Heuser M; Paschka P; Gaidzik VI; Saadati M; Benner A; Schlenk RF; Döhner K; Ganser A;
Lancet Haematol; 2023 Jul; 10(7):e495-e509. PubMed ID: 37187198
[TBL] [Abstract][Full Text] [Related]
14. Nucleophosmin mutations confer an independent favorable prognostic impact in 869 pediatric patients with acute myeloid leukemia.
Xu LH; Fang JP; Liu YC; Jones AI; Chai L
Blood Cancer J; 2020 Jan; 10(1):1. PubMed ID: 31915364
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Role of Postinduction Minimal Residual Disease and Myeloid Sarcoma Type Extramedullary Involvement in Pediatric RUNX1-RUNX1T1 (+) Acute Myeloid Leukemia.
Lee JW; Kim S; Jang PS; Chung NG; Cho B; Im SA; Kim M
J Pediatr Hematol Oncol; 2020 Apr; 42(3):e132-e139. PubMed ID: 31688618
[TBL] [Abstract][Full Text] [Related]
16. Gemtuzumab Ozogamicin in
Schlenk RF; Paschka P; Krzykalla J; Weber D; Kapp-Schwoerer S; Gaidzik VI; Leis C; Fiedler W; Kindler T; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Horst HA; Koller E; Wulf G; Schleicher J; Bentz M; Greil R; Hertenstein B; Krauter J; Martens U; Nachbaur D; Abu Samra M; Girschikofsky M; Basara N; Benner A; Thol F; Heuser M; Ganser A; Döhner K; Döhner H
J Clin Oncol; 2020 Feb; 38(6):623-632. PubMed ID: 31851556
[TBL] [Abstract][Full Text] [Related]
17. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.
Gamis AS; Alonzo TA; Meshinchi S; Sung L; Gerbing RB; Raimondi SC; Hirsch BA; Kahwash SB; Heerema-McKenney A; Winter L; Glick K; Davies SM; Byron P; Smith FO; Aplenc R
J Clin Oncol; 2014 Sep; 32(27):3021-32. PubMed ID: 25092781
[TBL] [Abstract][Full Text] [Related]
18. Extramedullary leukemia in children with acute myeloid leukemia: A population-based cohort study from the Nordic Society of Pediatric Hematology and Oncology (NOPHO).
Støve HK; Sandahl JD; Abrahamsson J; Asdahl PH; Forestier E; Ha SY; Jahnukainen K; Jónsson ÓG; Lausen B; Palle J; Zeller B; Hasle H
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28333413
[TBL] [Abstract][Full Text] [Related]
19. Association of fludarabin, cytarabine, and fractioned gemtuzumab followed by hematopoietic stem cell transplantation for first-line refractory acute myeloid leukemia in children: A single-center experience.
Penel-Page M; Plesa A; Girard S; Marceau-Renaut A; Renard C; Bertrand Y
Pediatr Blood Cancer; 2020 Jun; 67(6):e28305. PubMed ID: 32307866
[TBL] [Abstract][Full Text] [Related]
20. Hyperleukocytosis predicts inferior clinical outcome in pediatric acute myeloid leukemia.
Xu LH; Wang JW; Wang Y; Yang FY
Hematology; 2020 Dec; 25(1):507-514. PubMed ID: 33317436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
